이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Clinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide Analogues

A Randomized, Double-blind, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of YKYY013 in Patients With HBeAg-negative Chronic Hepatitis B Virus Infection Treated With Nucleos(t)Ide Analogs

To evaluate the efficacy of YKYY013 in patients with chronic hepatitis B virus (HBV) infection with negative hepatitis B e antigen (HBeAg) and treated with nucleoside (acid) analogs (NA).

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

1)Evaluate the safety and tolerability of YKYY013 in patients with HBeAg-negative chronic HBV infection treated with NA; 2) Evaluate the pharmacokinetic (PK,with the serum drug concentration of YKYY013) and pharmacodynamic (PD,with reduction in HBsAg) characteristics of YKYY013 in patients with HBeAg-negative chronic HBV infection treated with NA; 3) Evaluate the immunogenicity of YKYY013 in patients with HBeAg-negative chronic HBV infection treated with NA.

연구 유형

중재적

등록 (추정된)

120

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100050
        • Beijing Friendship Hospital, affiliated with Capital Medical University
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Body Mass Index (BMI) between 18.0 to 32.0 kg/m^2 (inclusive) and body weight equal to or over 50 kg for male and 45 kg for female.
  2. Chronic HBV infection , with positive hepatitis B surface antigen (HBsAg) or HBV DNA for at least 6 months, and continuous stable treatment with a single nucleoside (acid) analogue (NA) for ≥ 6 months.

3)HBeAg-negative at screening; 4)100 IU/mL < HBsAg ≤ 5000 IU/mL at screening; 5)HBV DNA < 100 IU/mL at screening. 6) Medically approved contraception (e.g., intrauterine device, oral contraceptive, condom) during the trial and for 6 months after the last dose, Participants must not donate sperm or ova during the trial or for 6 months after the last dose.

7) The participants voluntarily participate in the study, and sign the Informed Consent Form (ICF) prior to screening.

Exclusion Criteria:

  1. Severe allergic reactions, non-allergic drug reactions, multiple drug allergies, or known hypersensitivity to the investigational drug or its excipients.

  2. Chronic liver disease other than chronic HBV infection (e.g., severe fatty liver, alcoholic, autoimmune, or inherited metabolic liver disease).

  3. Liver stiffness measurement (LSM) above 9 kPa at screening, or Metavir F3 or higher on biopsy within 1 year before screening.

  4. Current or past hepatic decompensation (e.g., esophagogastric variceal bleeding, ascites, hepatic encephalopathy).

  5. Liver cancer history, or imaging (ultrasound, MRI, CT) suggesting liver cancer, or alpha-fetoprotein (AFP) at least 50 ug/L.

  6. Cardiovascular events (e.g., stroke, transient ischemic attack, myocardial infarction, unstable angina, coronary bypass surgery, percutaneous coronary intervention, heart failure hospitalization) or clinically significant valvular heart disease. Other chronic diseases considered unsuitable by the investigator (e.g., respiratory, endocrine, immune, renal, hepatic, gastrointestinal, dermatologic, hematologic, neurologic).

  7. Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage) or bleeding tendency (e.g., recurrent gingival bleeding); cured disease without active or clinically significant bleeding may be enrolled at investigator discretion.

  8. Severe infection within 1 month, or infection symptoms within 7 days, before screening.

  9. Major illness or major surgery (excluding minor outpatient procedures) within 3 months before screening, or planned grade 3-4 surgery during the trial.

  10. Malignancy within 5 years, except cured resected in situ carcinoma (e.g., non-melanoma skin cancer).

  11. Clinically significant abnormalities on physical examination, vital signs, 12-lead electrocardiogram (ECG), or chest CT at screening.

  12. Uncontrolled blood pressure at screening (systolic at least 160 mmHg or diastolic at least 100 mmHg despite treatment).

  13. Fridericia-corrected QT interval (QTcF) at least 450 msec (male) or 470 msec (female); if the first ECG exceeds these limits, two more ECGs are done and the mean of three applies.

  14. Significant laboratory abnormalities at screening, including:

    1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) at least 2 times the upper limit of normal (ULN).
    2. Total bilirubin at least 2 times ULN with direct bilirubin above ULN.
    3. Serum albumin below 35 g/L.
    4. Platelets below 100 x 10^9/L.
    5. Prothrombin time (PT) prolonged by more than 3 seconds, international normalized ratio (INR) above 1.3, or clinically significant fibrinogen abnormality.
    6. Creatinine clearance (Cockcroft-Gault) 60 mL/min or less, or clinically significant proteinuria.
    7. Poorly controlled diabetes with glycated hemoglobin (HbA1c) above 7.0%.
  15. AIDS, hepatitis A, B, C, or D, or positive screening for HIV antibody, Treponema pallidum antibody, or hepatitis A, B, C, or D antibody; positive hepatitis C antibody requires HCV RNA testing, and positive HCV RNA excludes.

  16. Any potentially hepatotoxic drug (prescription, over-the-counter, or herbal) within 14 days (or 5 half-lives, if longer) before the first dose, if judged unsuitable by the investigator; stable therapy for hypertension or diabetes is allowed.

  17. Interferon or immunosuppressant treatment within 12 months before screening, excluding short-term (2 weeks or less) use and topical or inhaled corticosteroids.

  18. Live vaccine within 1 month before screening.

  19. Small interfering RNA (siRNA) drug trial within 6 months, or other investigational drug within 3 months, before screening; or planned participation in another interventional trial.

  20. Severe intolerance to subcutaneous injection (mild local reactions are acceptable).

  21. Difficult venous access or venipuncture intolerance; history of syncope or hematophobia.

  22. Pregnancy, lactation, or positive pregnancy test at screening or baseline.

  23. Any scientific, compliance, or safety reason for which the investigator considers participation unsuitable.

  24. Inability to communicate or cooperate due to neurologic or psychiatric disorder or language barrier.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: YKYY013

Drug: YKYY013 Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week.

Drug: YKYY013 Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week.

위약 비교기: YKYY013 Placebo

Drug: 0.9% Sodium Chloride Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week.

Drug: 0.9% Sodium Chloride Injection Administration method: Administer subcutaneous injections according to the dose groups A/B/C/D every 4 weeks until the 48th week.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
The proportion (percent) of participants who achieved serum HBsAg < LLOQ (0.05 IU/mL) and HBVDNA < LLOQ at the 24th week
기간: Week 24
Week 24

2차 결과 측정

결과 측정
기간
The proportion (percent) of trial participants who maintained sustained efficacy during the 24-week period after discontinuation of YKYY013 (the NA monotherapy period, up to W72) after completing the YKYY013 treatment course.
기간: Week 72
Week 72
The proportion (percent) of participants who achieved serum HBsAg < LLOQ (0.05 IU/mL) and HBV DNA < LLOQ at the end of YKYY013 treatment.
기간: Week 48
Week 48
The proportion (percent) of trial participants who met the NA drug discontinuation criteria and stopped all chronic hepatitis B treatments (YKYY013 and NA drugs) and maintained sustained efficacy during a 24-week period.
기간: Week 72,Week 96
Week 72,Week 96
The proportion (percent) of trial participants who met the discontinuation criteria for NA treatment at the 72nd week
기간: Week 72
Week 72
Compared to the baseline level, the percentage (percent) of participants in the HBsAg test at different levels was reduced (e.g., ≥0.5, ≥1, ≥1.5, ≥2.0, ≥3 log10 IU/mL);
기간: From the first day to the 96th week
From the first day to the 96th week
The detection values (IU/mL) of HBsAg;
기간: From the first day to the 96th week
From the first day to the 96th week
The maximum reductions (IU/mL) of HBsAg from the baseline;
기간: From the first day to the 96th week
From the first day to the 96th week
The relative changes (IU/mL)of HBsAg from the baseline;
기간: From the first day to the 96th week
From the first day to the 96th week
The detection values (copies/ml) of HBV RNA;
기간: From the first day to the 96th week
From the first day to the 96th week
The maximum reductions (copies/ml) of HBV RNA from the baseline;
기간: From the first day to the 96th week
From the first day to the 96th week
The relative changes (copies/ml) of HBV RNA from the baseline;
기간: From the first day to the 96th week
From the first day to the 96th week
The detection values (U/mL) of HBcrAg;
기간: From the first day to the 96th week
From the first day to the 96th week
The maximum reductions (U/mL) of HBcrAg from the baseline;
기간: From the first day to the 96th week
From the first day to the 96th week
The relative changes (U/mL) of HBcrAg from the baseline;
기간: From the first day to the 96th week
From the first day to the 96th week
The detection values (IU/mL) of HBV DNA;
기간: From the first day to the 96th week
From the first day to the 96th week
The maximum reductions (IU/mL) of HBV DNA from the baseline;
기간: From the first day to the 96th week
From the first day to the 96th week
The relative changes (IU/mL) of HBV DNA from the baseline;
기간: From the first day to the 96th week
From the first day to the 96th week
The number and percentage (percent) of trial participants whose HBsAg and/or HBV DNA levels have dropped below the quantitative limit;
기간: From the first day to the 96th week
From the first day to the 96th week
The number and percentage (percent) of trial participants whose highly sensitive HBsAg (LLOQ ≤ 0.005 IU/mL) decreased below the quantitative limit;
기간: From the first day to the 96th week
From the first day to the 96th week
The positive rate (percent) and detection concentration (IU/L) of hepatitis B virus surface antibody (HBsAb);
기간: From the first day to the 96th week
From the first day to the 96th week
The positive rate (percent) of hepatitis B virus e antibody (HBeAb).
기간: From the first day to the 96th week
From the first day to the 96th week
Adverse events during treatment (TEAE)
기간: From the first day to the 96th week
From the first day to the 96th week
Number of participants with abnormally elevated body temperature.
기간: From the first day to the 96th week
From the first day to the 96th week
Number of participants with reactions at the injection site from prior administration.
기간: From the first day to the 96th week
From the first day to the 96th week
Number of participants with abnormal time between the start of the q wave and the end of the t wave (QT/QTc interval) on 12-lead electrocardiogram (ECG).
기간: From the first day to the 96th week
From the first day to the 96th week
Number of participants with liver function abnormalities during the treatment period.
기간: From the first day to the 96th week
From the first day to the 96th week
The number and proportion of participants with positive anti-drug antibodies (ADA).
기간: Day 1, Day 169, Day 337, Day 505, Day 673, or Early Termination; sampling time windows consistent with visit windows; pre-dose on dosing days
Day 1, Day 169, Day 337, Day 505, Day 673, or Early Termination; sampling time windows consistent with visit windows; pre-dose on dosing days

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 10월 30일

기본 완료 (추정된)

2027년 3월 20일

연구 완료 (추정된)

2029년 3월 14일

연구 등록 날짜

최초 제출

2026년 10월 21일

QC 기준을 충족하는 최초 제출

2026년 11월 11일

처음 게시됨 (실제)

2026년 11월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • CLSP-YKYY013-Z02

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .